Phase 1 Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with type 1 or type 2 diabetes, confirmed using standard medical guidelines.
- You are able to follow the study instructions and are expected to attend all required visits and complete all study steps.
- You agree to use reliable birth control during the study, and if you are a woman who could become pregnant, you agree to take a pregnancy test before joining.
- You have a specific type of eye problem related to diabetes called diabetic macular edema (swelling in the central part of the retina), confirmed by a special eye scan at your screening visit.
- Your vision in the study eye meets a minimum level, roughly 20/200 or better, as measured by a standardized eye chart test at your screening visit.
- Your eye doctor confirms that laser treatment or injections for your eye condition are either not needed right now or can safely be delayed for at least 3 months after your screening visit, or you have chosen not to have those treatments.
- Your eyes can be examined clearly, meaning pupils can be dilated enough to get good quality images of the retina.
Who may not be able to join:
- Your diabetes or blood pressure is not well controlled or is considered unstable.
- Your body weight is either too low or too high for the study (body mass index below 18.5 or above 28 kg/m²).
- You are currently taking, or are likely to need, certain medications known to be harmful to the eye or optic nerve, such as Deferoxamine, Chloroquine, Hydroxychloroquine, Tamoxifen, Phenothiazines, or Ethambutol.
- You have had a heart attack, stroke, mini-stroke (TIA), heart failure treatment, or a serious heart rhythm problem requiring hospital care within the 4 months before your screening visit.
- There is any other reason the study doctor believes it would not be safe for you to participate, that you may not be able to follow the study requirements, or that your situation could affect the study results (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kai Zhang, MD, Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Phone: +8613421382136
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Treatment-emergent adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.